April 05, 2024
2 min watch
Save
VIDEO: Aurion aims to end corneal endothelial disease with cell therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses the company’s cell therapy for corneal endothelial disease.
Kunst said the company is nearing completion of its phase 1/2 trial, and recent data have provided valuable insight as Aurion moves into phase 3 trials and its commercialization strategy.
“We have a product that has been in over 130 subjects in our early trials,” he said. “We have a product that we can scale massively and really take this around the world to end the scourge of corneal endothelial disease.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kunst reports being an employee of Aurion Biotech.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.